Stockscreener 앱 받기
103.40
3.37%
-3.61
Kymera Therapeutics Inc 주식(KYMR)의 최신 뉴스
KYMR Maintained by Guggenheim -- Price Target Raised to $135 - GuruFocus
Guggenheim raises Kymera Therapeutics price target on IRF5 program By Investing.com - Investing.com Canada
KYMR Looks 356.6% Overvalued on GF Value™ - GuruFocus
Form 4 Kymera Therapeutics Inc For: 27 July By Investing.com - Investing.com South Africa
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer - Investing News Network
Kymera Therapeutics names Terence Rooney as chief medical officer - Investing.com
Kymera Therapeutics names Terence Rooney as new Chief Medical Officer to lead clinical development. - Pluang
Kymera Therapeutics (NASDAQ: KYMR) names Terence Rooney as new CMO - Stock Titan
Johnson & Johnson Immunology Leader Joins Kymera as Chief Medical Officer - Stock Titan
Kymera Therapeutics officers probed for possible self-dealing, shareholders urged to act. - Pluang
Kymera Therapeutics Inc (KYMR) Cash Flow - TradingKey
Kymera Therapeutics Inc (KYMR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Kymera Therapeutics Inc (KYMR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
KYMR|Kymera Therapeutics Inc|Price:110.570|Chg%:+0.190 - TradingKey
KYMR|Kymera Therapeutics Inc|Price:110.320|Chg%:-0.250 - TradingKey
Is Kymera Therapeutics Poised for a Breakthrough With KT-621? - Yahoo Finance
Kymera Therapeutics Inc (KYMR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
💪💪💪💪💪💪💪💪💪💪💪 - Moomoo
Kymera Therapeutics stock slips to $111.06 amid selling pressure and volatile trading - Traders Union
Kymera Therapeutics, Inc. (KYMR) Stock Analysis: A Promising Biotech with a 12.68% Upside - DirectorsTalk Interviews
(KYMR) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Law firm probes Kymera Therapeutics' officers f... - Pluang
KYMR Maintained by Mizuho -- Price Target Raised to $140 - GuruFocus
Piper Sandler Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $140 - Moomoo
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR) - PR Newswire
Kymera Therapeutics Price Target Raised to $140.00/Share From $120.00 by Mizuho - Moomoo
Mizuho Securities Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $140 - Moomoo
Kymera Therapeutics (KYMR) AGM 2024 Summary - Quartr
Kymera Therapeutics (KYMR) Jefferies London Healthcare Conference 2025 Summary - Quartr
Kymera Therapeutics (KYMR) 44th Annual J.P. Morgan Healthcare Conference Summary - Quartr
Form 144 Kymera Therapeutics For: 13 July By Investing.com - Investing.com Nigeria
RBC Capital Markets has adjusted its investment rating for Kymera Therapeutics Inc., downgrading it from "outperform" to "sector perform." - Bitget
Kymera Therapeutics Shares Fall After RBC Downgrade - Moomoo
RBC Downgrades Kymera Therapeutics to Sector Perform From Outperform, Lifts Price Target to $115 From $106, Keeps Speculative Risk - marketscreener.com
Kymera's CEO Sold $6 Million in Stock After a 170% Run - The Globe and Mail
Kymera's CEO Sold $6 Million in Stock After a 170% Run - The Motley Fool
BTIG maintains Kymera Therapeutics (KYMR) buy recommendation - MSN
Strength seen in Kymera Therapeutics (KYMR): Can its 16.6% jump turn into more strength? - MSN
Is Kymera (KYMR) the Best Performing American Stock in June 2026? - Insider Monkey
Kymera jumps 17% on early enrollment completion in skin disease study - MSN
Kymera's High-Flying Stock Meets Insider Selling - Kavout | AI
Hedge Fund and Insider Trading News: Bill Ackman, Ken Griffin, Warren Buffett, Ray Dalio, Scion Asset Management, Brevan Howard, Kymera Therapeutics Inc (KYMR), Sony Group Corp (SONY), and More - Insider Monkey
Kymera Therapeutics Insider Sold Shares Worth $5,950,000, According to a Recent SEC Filing - marketscreener.com
Kymera Therapeutics (KYMR) Citi's Biopharma Back to School Conference Summary - Quartr
Kymera Therapeutics(KYMR.US) Officer Sells US$5.95 Million in Common Stock - Moomoo
Form 4 Kymera Therapeutics Inc For: 7 July By Investing.com - Investing.com Canada
Kymera Therapeutics CEO Mainolfi sells $5.95m in stock By Investing.com - Investing.com India
Kymera Therapeutics CEO Mainolfi sells $5.95m in stock - Investing.com
Form 144 Kymera Therapeutics For: 7 July By Investing.com - Investing.com Nigeria
Kymera Therapeutics, Inc. Announces Appointment of Elizabeth Laws as Senior Vice President - marketscreener.com
Kymera hires ex-Sanofi executive to lead KT-621 development - Investing.com
Kymera hires ex-Sanofi executive to lead KT-621 development By Investing.com - Investing.com South Africa
Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader - The Manila Times
2.44%
0.02%
자본화:
|
볼륨(24시간):